Home » FDA Grants Priority Review to Mallinckrodt’s MNK-795
FDA Grants Priority Review to Mallinckrodt’s MNK-795
The FDA has accepted for priority review Mallinckrodt’s NDA for MNK-795, a controlled-release combination of oxycodone and acetaminophen.
PharmTech
PharmTech
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May